These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 2972431

  • 1. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L.
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [Abstract] [Full Text] [Related]

  • 2. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R, Lachance R, Dupont A, Labrie F.
    Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
    [Abstract] [Full Text] [Related]

  • 3. The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole.
    Lacoste D, St-Arnaud R, Caron S, Belanger A, Labrie F.
    J Steroid Biochem; 1988 Dec; 31(6):963-70. PubMed ID: 3059065
    [Abstract] [Full Text] [Related]

  • 4. Effect of 3-week treatment with [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog.
    Lacoste D, Caron S, Bélanger A, Labrie F.
    J Steroid Biochem; 1989 Aug; 33(2):233-42. PubMed ID: 2671505
    [Abstract] [Full Text] [Related]

  • 5. Characteristics of flutamide action on prostatic and testicular functions in the rat.
    Marchetti B, Labrie F.
    J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
    [Abstract] [Full Text] [Related]

  • 6. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
    Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M.
    Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Sep; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 8. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
    St-Arnaud R, Lachance R, Kelly SJ, Belanger A, Dupont A, Labrie F.
    Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
    [Abstract] [Full Text] [Related]

  • 9. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G, Linde R, Alexander N, Kirchner F, Vale W, Rivier J, Rabin D.
    Int J Fertil; 1982 Jan; 27(4):234-7. PubMed ID: 6131043
    [Abstract] [Full Text] [Related]

  • 10. Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate.
    Brochu M, Bélanger A, Dupont A, Cusan L, Labrie F.
    J Steroid Biochem; 1987 Dec; 28(6):619-22. PubMed ID: 2961945
    [Abstract] [Full Text] [Related]

  • 11. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D, Dubé D, Bélanger A, Labrie F.
    Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
    [Abstract] [Full Text] [Related]

  • 12. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
    Labrie F, Dupont A, Bélanger A, Lacourcière Y, Béland L, Cusan L, Lachance R.
    Clin Invest Med; 1990 Oct; 13(5):275-8. PubMed ID: 2276222
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
    Lukkarinen O, Hammond GL, Kontturi M, Vihko R.
    Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
    [Abstract] [Full Text] [Related]

  • 14. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM, Chertin B, Fridmans A, Farkas A, Belanger A, Hartman H, Labrie F.
    Prostate Cancer Prostatic Dis; 2009 Jan; 12(1):100-3. PubMed ID: 18574491
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
    Labrie F, Dupont A, Cusan L, Bélanger A, Giguère M, Labrie C, Lacourcière Y, Monfette G, Emond J.
    Prog Clin Biol Res; 1988 Jan; 262():11-63. PubMed ID: 3287388
    [No Abstract] [Full Text] [Related]

  • 16. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R, Lachance R, Dupont A, Labrie F.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [Abstract] [Full Text] [Related]

  • 17. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević Z.
    Neoplasma; 1997 Aug; 44(5):308-13. PubMed ID: 9473791
    [Abstract] [Full Text] [Related]

  • 18. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
    Cochran RC, Ewing LL, Niswender GD.
    Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
    [Abstract] [Full Text] [Related]

  • 19. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, Husson JM.
    Clin Invest Med; 1982 Nov; 5(4):267-75. PubMed ID: 6819101
    [Abstract] [Full Text] [Related]

  • 20. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P.
    Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.